Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ex-vivo Rituximab for PTLD Prevention in Lung Transplant
NCT04507477Phase 2Unknown
- Sponsor
- University Health Network
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by University Health Network. Primary endpoint: Number of patients with Primary Graft Dysfunction at 1 week. Status: unknown.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT04507477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507477.